- Home
- BBN vs APLT Comparison
BBN vs APLT Comparison
Compare BBN & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BBN
- APLT
- Stock Information
- Founded
- BBN 1983
- APLT 2016
- Country
- BBN United States
- APLT United States
- Employees
- BBN N/A
- APLT N/A
- Industry
- BBN Finance Companies
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- BBN Finance
- APLT Health Care
- Exchange
- BBN Nasdaq
- APLT Nasdaq
- Market Cap
- BBN 1.0B
- APLT 128.0M
- IPO Year
- BBN N/A
- APLT 2019
- Fundamental
- Price
- BBN $16.12
- APLT $0.90
- Analyst Decision
- BBN
- APLT Buy
- Analyst Count
- BBN 0
- APLT 7
- Target Price
- BBN N/A
- APLT $6.10
- AVG Volume (30 Days)
- BBN 231.8K
- APLT 8.4M
- Earning Date
- BBN 01-01-0001
- APLT 11-07-2024
- Dividend Yield
- BBN 6.90%
- APLT N/A
- EPS Growth
- BBN N/A
- APLT N/A
- EPS
- BBN N/A
- APLT N/A
- Revenue
- BBN N/A
- APLT N/A
- Revenue This Year
- BBN N/A
- APLT N/A
- Revenue Next Year
- BBN N/A
- APLT $2,664.24
- P/E Ratio
- BBN N/A
- APLT N/A
- Revenue Growth
- BBN N/A
- APLT N/A
- 52 Week Low
- BBN $14.33
- APLT $0.77
- 52 Week High
- BBN $18.36
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- BBN 39.62
- APLT 19.46
- Support Level
- BBN $17.08
- APLT $0.78
- Resistance Level
- BBN $16.17
- APLT $0.90
- Average True Range (ATR)
- BBN 0.23
- APLT 0.12
- MACD
- BBN -0.03
- APLT 0.26
- Stochastic Oscillator
- BBN 23.33
- APLT 20.97
About BBN BlackRock Taxable Municipal Bond Trust of Beneficial Interest
BlackRock Taxable Municipal Bond Trust is a diversified, closed-end management investment company. Its investment objective is to seek high current income, with a secondary objective of capital appreciation.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.